The Latest Cardiac and Vascular News
Proven medtech leader appointed to chair AI-powered cardiovascular technology through commercialization and expansion BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors. “There are few […]
WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten public offering of 3,686,006 shares of common stock, and warrants to purchase up […]
1Q Revenue growth of 8% year-over-year; Organic revenue* growth of 12% 1Q Net income attributable to GE HealthCare of $372 million versus $389 million for the prior year, Adjusted EBIT* of $664 million versus $599 million 1Q Diluted EPS was $0.41 versus $0.86 in the prior year, Adjusted EPS* was […]
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 25 April 2023, 06:15 am CEST Ghent, Belgium, 25 April 2023 – Sequana Medical NV (Euronext Brussels: […]
SEOUL, South Korea, April 25, 2023 /PRNewswire/ — Mezzion Pharma (“Mezzion”), a rare disease focused pharmaceutical company, announced that it has secured nearly $40M USD to fund FUEL-2, their confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to bring to market JURVIGO® (udenafil), a […]
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating income +18% (cc, +11% USD) IM core margin 38.7%, +360 bps cc, driven by […]
Copenhagen-based research center is awarded up to DKK 1 billion (€134.2 million) from the Novo Nordisk Foundation to support research toward innovative approaches to the diagnosis, prevention, and treatment of cardiometabolic diseases. COPENHAGEN, Denmark , April 25, 2023 /PRNewswire/ — The prevalence of cardiometabolic diseases such as diabetes, obesity and cardiovascular disease continues to increase […]
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first […]
LONDON, April 24, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq […]
First-quarter highlights Group sales increased to EUR 4.2 billion, with 6% comparable sales growth Comparable order intake growth was flat, with double-digit growth in the Diagnosis & Treatment businesses, offset by a decline in the Connected Care businesses Income from operations amounted to a loss of EUR 583 million, mainly […]
